盘龙药业：关于公司获得药物临床试验批准通知书的公告

Core Viewpoint - The announcement by Panlong Pharmaceutical regarding the approval of clinical trials for Ketoprofen gel patches indicates a significant step in the development of pain relief treatments, particularly for osteoarthritis [1] Company Summary - Panlong Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Ketoprofen gel patches [1] - The product is a chemical drug in the 3rd category, with specifications of 14cm×10cm containing 30mg of Ketoprofen [1] - Currently, the only other company with a similar product approved for market in China is Hunan Jiudian Pharmaceutical [1] Industry Summary - The approval of Ketoprofen gel patches highlights the ongoing development and competition in the pain relief market, particularly for localized treatments for conditions like osteoarthritis [1] - The market for such products may see increased activity as more companies seek to develop and approve similar pain management solutions [1]